Brian D. Lamon

661 total citations
17 papers, 522 citations indexed

About

Brian D. Lamon is a scholar working on Immunology, Molecular Biology and Physiology. According to data from OpenAlex, Brian D. Lamon has authored 17 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Molecular Biology and 5 papers in Physiology. Recurrent topics in Brian D. Lamon's work include Nitric Oxide and Endothelin Effects (5 papers), Neonatal Health and Biochemistry (4 papers) and Heme Oxygenase-1 and Carbon Monoxide (4 papers). Brian D. Lamon is often cited by papers focused on Nitric Oxide and Endothelin Effects (5 papers), Neonatal Health and Biochemistry (4 papers) and Heme Oxygenase-1 and Carbon Monoxide (4 papers). Brian D. Lamon collaborates with scholars based in United States, Netherlands and Italy. Brian D. Lamon's co-authors include David P. Hajjar, Ruba S. Deeb, Rita K. Upmacis, Steven S. Gross, Alberto Nasjletti, Nader G. Abraham, Alvin I. Goodman, Rita Rezzani, John R. Falck and Bhavani Sangras and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Brian D. Lamon

17 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian D. Lamon United States 11 212 89 75 75 73 17 522
Dilinaer Bolati Japan 9 284 1.3× 134 1.5× 55 0.7× 62 0.8× 70 1.0× 10 760
Gulinuer Muteliefu Japan 8 186 0.9× 127 1.4× 41 0.5× 54 0.7× 71 1.0× 9 699
Dhruv K. Singh United Kingdom 11 202 1.0× 119 1.3× 37 0.5× 49 0.7× 104 1.4× 19 798
Maha Abdelrahman United Kingdom 9 275 1.3× 83 0.9× 58 0.8× 78 1.0× 66 0.9× 13 606
Kengo Kidokoro Japan 18 318 1.5× 97 1.1× 37 0.5× 68 0.9× 215 2.9× 34 952
Maivel H. Ghattas Egypt 15 466 2.2× 43 0.5× 71 0.9× 46 0.6× 60 0.8× 39 736
Nicholas J. Lamb United Kingdom 12 310 1.5× 151 1.7× 64 0.9× 101 1.3× 48 0.7× 13 753
Hideyuki Horike Japan 8 148 0.7× 134 1.5× 49 0.7× 58 0.8× 95 1.3× 24 679
Allison B. Lehtinen United States 13 158 0.7× 55 0.6× 58 0.8× 45 0.6× 63 0.9× 16 508
Christopher J. Mingone United States 10 364 1.7× 150 1.7× 72 1.0× 53 0.7× 36 0.5× 10 584

Countries citing papers authored by Brian D. Lamon

Since Specialization
Citations

This map shows the geographic impact of Brian D. Lamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian D. Lamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian D. Lamon more than expected).

Fields of papers citing papers by Brian D. Lamon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian D. Lamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian D. Lamon. The network helps show where Brian D. Lamon may publish in the future.

Co-authorship network of co-authors of Brian D. Lamon

This figure shows the co-authorship network connecting the top 25 collaborators of Brian D. Lamon. A scholar is included among the top collaborators of Brian D. Lamon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian D. Lamon. Brian D. Lamon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rozeman, Elisa A., Lorenzo F. Fanchi, Alexander C. J. van Akkooi, et al.. (2017). (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses. Annals of Oncology. 28. v432–v432. 10 indexed citations
2.
Rozeman, Elisa A., Christian U. Blank, Alexander Christopher Jonathan Van Akkooi, et al.. (2017). Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. Journal of Clinical Oncology. 35(15_suppl). 9586–9586. 20 indexed citations
3.
Akkooi, Alexander C. J. van, Elisa A. Rozeman, Pia Kvistborg, et al.. (2016). (Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial. Annals of Oncology. 27. vi575–vi575. 9 indexed citations
4.
Zhang, Haijun, Brian D. Lamon, George W. Moran, et al.. (2016). Pitavastatin Differentially Modulates MicroRNA-Associated Cholesterol Transport Proteins in Macrophages. PLoS ONE. 11(7). e0159130–e0159130. 8 indexed citations
5.
Deeb, Ruba S., Tal Nuriel, Cynthia Cheung, et al.. (2013). Characterization of a cellular denitrase activity that reverses nitration of cyclooxygenase. American Journal of Physiology-Heart and Circulatory Physiology. 305(5). H687–H698. 42 indexed citations
6.
Puri, Nitin, Fan Zhang, Komal Sodhi, et al.. (2012). Antioxidants Condition Pleiotropic Vascular Responses to Exogenous H 2 O 2 : Role of Modulation of Vascular TP Receptors and the Heme Oxygenase System. Antioxidants and Redox Signaling. 18(5). 471–480. 8 indexed citations
7.
Upmacis, Rita K., Hao Shen, Brian D. Lamon, et al.. (2011). Inducible nitric oxide synthase provides protection against injury-induced thrombosis in female mice. American Journal of Physiology-Heart and Circulatory Physiology. 301(2). H617–H624. 14 indexed citations
8.
Deeb, Ruba S., Cynthia Cheung, Tal Nuriel, et al.. (2010). Physical Evidence for Substrate Binding in Preventing Cyclooxygenase Inactivation under Nitrative Stress. Journal of the American Chemical Society. 132(11). 3914–3922. 12 indexed citations
9.
Lamon, Brian D., et al.. (2010). Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli. American Journal of Physiology-Heart and Circulatory Physiology. 299(3). H613–H623. 23 indexed citations
10.
Lamon, Brian D., Barbara D. Summers, Antonio M. Gotto, & David P. Hajjar. (2009). Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. European Journal of Pharmacology. 606(1-3). 72–76. 8 indexed citations
11.
Deeb, Ruba S., Brian D. Lamon, & David P. Hajjar. (2009). Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease. Current Hypertension Reviews. 5(4). 273–282. 5 indexed citations
12.
Lamon, Brian D., Feida Zhang, Nitin Puri, et al.. (2009). Dual Pathways of Carbon Monoxide–Mediated Vasoregulation. Circulation Research. 105(8). 775–783. 40 indexed citations
13.
Lamon, Brian D. & David P. Hajjar. (2008). Inflammation at the Molecular Interface of Atherogenesis. American Journal Of Pathology. 173(5). 1253–1264. 100 indexed citations
14.
Deree, Jessica, Joilson O. Martins, Brian D. Lamon, et al.. (2007). Hypertonic Saline and Pentoxifylline Reduces Hemorrhagic Shock Resuscitation-Induced Pulmonary Inflammation Through Attenuation of Neutrophil Degranulation and Proinflammatory Mediator Synthesis. The Journal of Trauma: Injury, Infection, and Critical Care. 62(1). 104–111. 37 indexed citations
15.
Deeb, Ruba S., Rita K. Upmacis, Brian D. Lamon, Steven S. Gross, & David P. Hajjar. (2007). Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways. Hypertension. 51(1). 1–7. 76 indexed citations
16.
Rodella, Luigi Fabrizio, Brian D. Lamon, Rita Rezzani, et al.. (2006). Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radical Biology and Medicine. 40(12). 2198–2205. 70 indexed citations
17.
Rodríguez, Francisca, et al.. (2003). Nitric Oxide Synthesis Inhibition Promotes Renal Production of Carbon Monoxide. Hypertension. 43(2). 347–351. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dilinaer Bolati Breakdown of academic impact, for papers by Gulinuer Muteliefu Breakdown of academic impact, for papers by Dhruv K. Singh Breakdown of academic impact, for papers by Maha Abdelrahman Breakdown of academic impact, for papers by Kengo Kidokoro Breakdown of academic impact, for papers by Maivel H. Ghattas Breakdown of academic impact, for papers by Nicholas J. Lamb Breakdown of academic impact, for papers by Hideyuki Horike Breakdown of academic impact, for papers by Allison B. Lehtinen Breakdown of academic impact, for papers by Christopher J. Mingone
Rankless by CCL
2026